Methylphenidate Hydrochloride

Introduction Overview

Generic Name

methylphenidate hydrochloride

Brand Name

QuilliChew ER

Dosage Form

oral extended-release chewable tablet

Drug Class

CNS stimulants

Pharmacokinetics

Absorption:
Methylphenidate hydrochloride, the active ingredient in QuilliChew ER, is well absorbed from the gastrointestinal tract when administered orally. The chewable extended-release formulation of QuilliChew ER is designed to release methylphenidate gradually throughout the day, prolonging its systemic availability and therapeutic effect. The chewable tablet allows for early onset since initial release occurs soon after administration, while the extended-release matrix maintains prolonged plasma concentrations. Absorption is not significantly affected by food intake, permitting dosing with or without meals. Peak plasma concentrations typically occur within 4 to 6 hours post-dose, reflecting the extended-release properties.

Distribution:
Once absorbed, methylphenidate is widely distributed throughout body tissues and crosses the blood-brain barrier to exert its central nervous system effects. It has a volume of distribution ranging between 2 to 3 L/kg. Methylphenidate exhibits moderate plasma protein binding (~10%-33%), primarily binding to plasma proteins such as albumin. Distribution is rapid, with CNS penetration essential for its pharmacodynamic activity. The ability of methylphenidate to concentrate in brain regions involved in attention and behavior regulation correlates with its clinical efficacy in ADHD treatment.

Metabolism:
Methylphenidate undergoes extensive first-pass metabolism primarily in the liver and plasma via de-esterification to ritalinic acid, an inactive metabolite. This biotransformation occurs mainly through carboxylesterase 1 (CES1) enzymes. The metabolic conversion significantly reduces the bioavailability of unchanged drug to approximately 30%. The ritalinic acid metabolite is pharmacologically inactive and does not contribute to therapeutic effects or adverse reactions. Genetic polymorphisms in CES1 can alter metabolism rates, impacting drug levels and clinical response in some patients.

Elimination:
The metabolites of methylphenidate, mainly ritalinic acid, are primarily excreted via the kidneys. About 90% of the dose is eliminated renally as inactive metabolites within 48 to 72 hours. The elimination half-life of methylphenidate is approximately 2 to 3 hours, but the extended-release delivery system prolongs effective plasma concentrations to cover a therapeutic window of around 8 to 12 hours. Renal impairment can affect clearance of metabolites but is not generally a major concern for dosage adjustment. Drug accumulation is minimal with recommended once-daily dosing.

Dosage Forms

Available Dosage Forms:
QuilliChew ER is available as an oral extended-release chewable tablet formulated with a cherry flavor to improve palatability, facilitating administration especially in children who have difficulty swallowing conventional tablets. The chewable tablets come in 20 mg, 30 mg, and 40 mg strengths. Specifically, the 20 mg and 30 mg tablets are scored (bisected) allowing for precise dose titration by cutting in half, while the 40 mg tablets are not scored and should not be divided.

Dosages for Adults and Adolescents:
The indicated population for QuilliChew ER therapy is individuals aged 6 years and older diagnosed with ADHD. The recommended starting dose is 20 mg orally once daily in the morning. Based on clinical response and tolerability, the dose may be adjusted weekly by increments or decrements of 10 mg, 15 mg, or 20 mg. The maximum daily dose recommended is 60 mg, beyond which safety and efficacy have not been established. Dose titration requires careful monitoring for both therapeutic benefits and potential adverse effects.

Specific Patient Populations:
QuilliChew ER has not been studied or demonstrated as safe and effective in children below 6 years of age; therefore, use in this age group is not recommended. In pediatric patients, monitoring growth (height and weight) is critical, as slowing growth velocity has been observed with methylphenidate use. Additionally, caution and individualized assessment are required in patients with pre-existing cardiovascular conditions, psychiatric disorders, or susceptibility to abuse. No dose adjustments are specifically recommended for elderly patients or those with renal or hepatic impairment; however, clinical monitoring is advised.

Additional Clinical Guidelines:
Dosing should always be personalized, with healthcare providers performing regular evaluations during dose titration and maintenance phases. Because QuilliChew ER provides extended symptom control throughout the day, it is important to administer the tablet in the morning to avoid insomnia. Intermittent drug holidays may be considered by clinicians to assess ongoing need and minimize adverse effects. Consistent adherence to prescribed dosing and not exceeding recommended doses is essential to reduce risk of toxicity and abuse.

Mechanism Of Action

QuilliChew ER contains methylphenidate hydrochloride, a central nervous system stimulant, which primarily exerts its therapeutic effects by modulating monoaminergic neurotransmission in the brain. The exact neurochemical mechanism responsible for its efficacy in attention deficit hyperactivity disorder (ADHD) is not fully elucidated, but it is known to increase the extracellular concentrations of dopamine and norepinephrine, neurotransmitters critical for attention, executive function, and behavioral control.

At the molecular level, methylphenidate acts by blocking the dopamine transporter (DAT) and norepinephrine transporter (NET) on presynaptic neuronal membranes in the CNS. By inhibiting the reuptake of dopamine and norepinephrine from the synaptic cleft back into the presynaptic neuron, methylphenidate prolongs the availability and action of these neurotransmitters at postsynaptic receptors. This leads to enhanced stimulation of dopamine D1 and D2 receptors and adrenergic receptors, particularly in key brain regions such as the prefrontal cortex and striatum, areas implicated in attention regulation and impulse control.

Cellular pathways affected include increased dopaminergic and noradrenergic signaling pathways, which enhance neuronal firing and synaptic transmission efficiency. The increased neurotransmitter availability is believed to normalize dysregulated neuronal circuits associated with ADHD symptoms. Additionally, methylphenidate may influence other neurotransmitter systems indirectly, including serotonin and glutamate, contributing to its complex pharmacodynamic profile.

Clinically, these biochemical interactions translate into improved attention span, decreased impulsivity, and reduced hyperactivity in patients with ADHD. The extended-release formulation of QuilliChew ER allows a gradual and sustained delivery of methylphenidate, maintaining stable plasma and CNS levels throughout the day, which supports continuous symptom control without the peaks and troughs seen with immediate-release formulations. Compared to other CNS stimulants such as amphetamines, methylphenidate has a similar effect on monoamine transporters but differs structurally and in abuse potential. Clinical trials support its efficacy and safety profile, with ongoing research further elucidating its impact on neurodevelopment and neuroplasticity in ADHD.

Pharmacological Actions

CNS stimulant activity predominantly through dopamine and norepinephrine reuptake inhibition
Enhanced catecholaminergic neurotransmission in prefrontal cortex and related brain regions
Improvement of attention span and reduction of hyperactivity/impulsivity symptoms in ADHD
Prolonged therapeutic effect due to extended-release formulation ensuring sustained plasma concentrations
Minimal impact on serotonergic pathways, thereby limiting serotonergic side effects
Potential modulation of circadian rhythm contributing to wakefulness during the day
Dose-dependent cardiovascular stimulation including modest increases in heart rate and blood pressure
Influence on neural circuits involved in executive function, working memory, and behavioral control
Reduction in fatigue and improvement in wakefulness in some populations
Neurochemical modulation contributing to behavioral and cognitive enhancements
Risk of psychological dependence associated with dopaminergic activity
Possible slowing of growth rate in pediatric patients with chronic administration
Suppressive effects on appetite linked to hypothalamic centers
Modulation of peripheral sympathetic nervous system activity
Impact on motor system facilitation through increased dopamine availability

Therapeutic Or Clinical Uses

Treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 years and older
Improvement of attention, focus, and reduction of impulsive behavior associated with ADHD
Management of hyperactivity symptoms to enhance daily functioning and academic performance
Use as part of a comprehensive treatment program including psychological, educational, and social interventions
Adjunctive therapy to facilitate behavioral modification in ADHD
Potential off-label use under specialist supervision for narcolepsy-related excessive daytime sleepiness (based on methylphenidate class data)
Temporary control of symptoms during acute exacerbations requiring stimulant intervention
Option for patients requiring once-daily dosing with extended symptom control
Use in patients who prefer or require chewable tablet formulations due to swallowing difficulties
Treatment modality with controlled release to minimize abuse potential compared to immediate-release stimulants
Selection for patients with previous poor adherence to other formulations due to convenience and taste
Consideration in patients without significant cardiac or psychiatric contraindications
Facilitation of improved social and occupational functioning through symptom management
Use in reducing ADHD-associated behavioral disturbances impacting quality of life
Use within a careful monitoring framework to adjust doses according to clinical response

Side Or Adverse Effects

Decreased appetite leading to potential weight loss, especially in pediatric patients
Trouble sleeping or insomnia due to CNS stimulation if taken late in the day
Nausea, vomiting, indigestion, and stomach pain affecting gastrointestinal comfort
Anxiety and nervousness which may exacerbate underlying psychiatric symptoms
Dizziness and headaches possibly related to central nervous system effects
Increased heart rate (tachycardia) and elevated blood pressure requiring monitoring
Mood swings and irritability, including potential worsening of bipolar disorder
Risk of priapism (painful and prolonged erections) requiring urgent medical attention
Potential for dependence, abuse, and psychological addiction owing to stimulant properties
Peripheral vasculopathy including Raynaud’s phenomenon characterized by numbness and color changes in extremities
Possible new or worsening psychiatric symptoms including psychosis, mania, and suicidal ideation
Slowing of growth (both height and weight gain) in children with chronic use
Fainting or cardiovascular events, especially in patients with underlying heart conditions
Rare allergic reactions including rash, itching, or anaphylaxis
Withdrawal symptoms or rebound hyperactivity upon abrupt discontinuation

Precautions

Use caution in patients with pre-existing cardiovascular disorders or risk factors
Monitor blood pressure and heart rate regularly during treatment
Assess mental health history and monitor for emergence or worsening of psychiatric symptoms
Avoid use in patients currently or recently treated with monoamine oxidase inhibitors (MAOIs)
Use cautiously in patients with a history of drug or alcohol abuse due to high abuse potential
Be aware of the presence of phenylalanine in formulation due to aspartame, especially in phenylketonuria (PKU)
Regularly monitor growth parameters in pediatric patients and consider dose adjustments or drug holidays
Inform patients and caregivers about potential for serious side effects and signs requiring immediate attention
Avoid concomitant use with other sympathomimetic agents without medical supervision
Consider the risk-benefit ratio in pregnant or breastfeeding patients due to limited safety data
Advise against sharing medication due to legal and health risks
Evaluate necessity of treatment periodically to minimize long-term adverse effects
Use caution in patients with seizure disorders as stimulant drugs may lower seizure threshold
Adapt dosing carefully in elderly patients who may be more sensitive to stimulant effects
Educate patients on the importance of adherence to prescribed dosing schedules

Warnings

High potential for abuse and risk of physical and psychological dependence
Serious cardiovascular events including sudden death, stroke, and myocardial infarction reported, especially in adults with known cardiac disease
Risk of sudden death in children with underlying structural heart abnormalities or cardiac defects
New or exacerbated psychiatric conditions such as psychosis, mania, and bipolar disorder can occur
Circulation problems in fingers and toes (peripheral vasculopathy), including Raynaud’s phenomenon
Risk of priapism requiring immediate medical intervention to prevent permanent damage
Use contraindicated with monoamine oxidase inhibitors (MAOIs) and within 14 days of discontinuation
Potential for severe hypertension in susceptible individuals
Not established as safe or effective in children under 6 years of age
Risk of growth suppression with chronic use in pediatric populations
Sudden discontinuation may precipitate withdrawal symptoms or exacerbation of ADHD symptoms
Use during pregnancy only if clearly needed; effects on fetus unknown
Exposure during breastfeeding requires careful consideration due to excretion into breast milk
Patients with a family history of sudden cardiac death require cardiac evaluation prior to initiating therapy
Label includes FDA black-box warning highlighting abuse and dependency potential

Contraindication

Hypersensitivity to methylphenidate hydrochloride or any component of the formulation
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping an MAOI
Patients with marked anxiety, tension, or agitation as stimulants may exacerbate these conditions
Known structural heart defects, cardiomyopathy, serious cardiac arrhythmias, or other significant cardiac disease
Glaucoma due to potential increased intraocular pressure from stimulant effect
Tourette syndrome or family history of Tourette's syndrome because of risk of exacerbating tics
Severe hypertension or uncontrolled hypertension
Hyperthyroidism or thyrotoxicosis where stimulants can worsen the clinical state
Patients with a history of drug or alcohol abuse not adequately monitored for potential abuse
Use in children younger than 6 years due to lack of safety and efficacy data
Concurrent treatment with other stimulants or sympathomimetic agents unless directed by physician
Phenylketonuria patients should avoid due to phenylalanine content from aspartame
Severe anxiety or psychosis currently active
Patients with a history of seizures unless benefits outweigh risks and under close supervision
Pregnancy and breastfeeding only if benefits justify potential risks as no definitive safety established

Drug Interactions

Contraindicated with monoamine oxidase inhibitors (MAOIs); may cause hypertensive crisis
Additive cardiovascular effects when used with other sympathomimetic agents, increasing risk of hypertension and tachycardia
Potential interaction with antihypertensive agents reducing their efficacy due to stimulant effects
May augment the effects and toxicity of serotonergic drugs, raising concern for serotonin syndrome
Concurrent use with anticonvulsants requires monitoring as methylphenidate may alter seizure threshold
Possible increased plasma concentrations when used with CYP2D6 inhibitors
Synergistic effect with other CNS stimulants leading to increased side effects
Interaction with antipsychotics potentially reducing their efficacy by opposing dopaminergic blockade
Use with tricyclic antidepressants may increase cardiac toxicity and require close cardiovascular monitoring
Alcohol consumption may accelerate methylphenidate release from extended-release formulation, increasing toxicity risk
Potential interference with anticonvulsant blood levels necessitating therapeutic drug monitoring
Interaction with blood pressure medications may require dosage adjustments to maintain blood pressure control
Methylphenidate may increase effects of coumarin anticoagulants necessitating more frequent INR monitoring
Concomitant use with selective serotonin reuptake inhibitors (SSRIs) should be monitored for behavioral or neuropsychiatric side effects
Supplements or herbal products with CNS stimulant properties may enhance stimulant effects and increase adverse reactions

Preparations Of The Drug

Extended-release chewable tablets in strengths of 20 mg (scored), 30 mg (scored), and 40 mg (non-scored)
Cherry-flavored formulation designed to improve palatability and ease administration, particularly in pediatric patients
Inclusion of artificial sweetener aspartame, which contains phenylalanine, requiring caution in PKU patients
Inactive excipients include citric acid, crospovidone, D&C red #30 or #7 depending on strength, guar gum, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl acetate, polyvinyl alcohol, povidone, silicon dioxide, sodium polystyrene sulfonate, talc, triacetin, xanthan gum
Formulated for once-daily morning dosing to provide extended symptom control throughout the waking day
Tablets may be split only if scored, allowing flexible dosing; the 40 mg tablets must be taken whole
Packaged in bottles with secure caps to mitigate risk of pediatric access and abuse
Manufactured by Tris Pharma, Inc., ensuring adherence to FDA regulations and quality control standards
Available only by prescription due to controlled substance status (Schedule II)
Designed to have a biphasic release profile combining immediate and extended-release components for optimal therapeutic effect
Contains dye components D&C red #30 or #7 which may pose allergy considerations
Stability requires storage at room temperature, protected from moisture and light
Strict regulations surrounding distribution and dispensing to prevent diversion and misuse
Labeling includes comprehensive warnings related to abuse potential and safety monitoring
Provision of medication guides and patient counseling information mandated by regulatory agencies